Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Burger

Showing results (1111-1120 of 1,155) with videos related to

Pageof 116
Sort By:
Cell|December 22, 2015
Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing EpitopesSteven W de Taeye, Gabriel Ozorowski, Alba Torrents de la Peña, et al.
Elife|November 23, 2021
Cross-reactive antibodies after SARS-CoV-2 infection and vaccinationMarloes Grobben, Karlijn van der Straten, Philip Jm Brouwer, et al.
Cancer Cell|March 12, 2015
Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemiaHuimin Geng, Christian Hurtz, Kyle B Lenz, et al.
JAMA Oncology|December 21, 2023
Abandonment of Routine Radiotherapy for Nonlocally Advanced Rectal Cancer and Oncological OutcomesSanne-Marije J A Hazen, Tania C Sluckin, Martijn P W Intven, et al.
Nature Communications|May 31, 2019
Structure and immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus sequenceKwinten Sliepen, Byung Woo Han, Ilja Bontjer, et al.
The Lancet. Gastroenterology & Hepatology|August 3, 2019
Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trialCharlotte E L Klaver, Daniel D Wisselink, Cornelis J A Punt, et al.
Eclinicalmedicine|June 20, 2023
Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI): a cohort studyQuincy Hofsink, Sabine Haggenburg, Birgit I Lissenberg-Witte, et al.
JAMA Oncology|August 11, 2022
Antibody Response in Immunocompromised Patients With Hematologic Cancers Who Received a 3-Dose mRNA-1273 Vaccination Schedule for COVID-19Sabine Haggenburg, Quincy Hofsink, Birgit I Lissenberg-Witte, et al.
Gynecologic Oncology|July 1, 2026
Updated patient-reported outcomes and the effect of disease progression on health-related quality of life in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancerMark S Shahin, Domenica Lorusso, Floor J Backes, et al.
Nature Immunology|February 3, 2026
Identification of a potent V3 glycan site broadly neutralizing antibody targeting an N332<sub>gp120</sub> glycan-independent epitopeLutz Gieselmann, Andrew T DeLaitsch, Malena Rohde, et al.
Pageof 116

Showing results (1111-1120 of 1,155) with videos related to

Sort By:
Pageof 116
Cell|December 22, 2015
Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing EpitopesSteven W de Taeye, Gabriel Ozorowski, Alba Torrents de la Peña, et al.
Elife|November 23, 2021
Cross-reactive antibodies after SARS-CoV-2 infection and vaccinationMarloes Grobben, Karlijn van der Straten, Philip Jm Brouwer, et al.
Cancer Cell|March 12, 2015
Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemiaHuimin Geng, Christian Hurtz, Kyle B Lenz, et al.
JAMA Oncology|December 21, 2023
Abandonment of Routine Radiotherapy for Nonlocally Advanced Rectal Cancer and Oncological OutcomesSanne-Marije J A Hazen, Tania C Sluckin, Martijn P W Intven, et al.
Nature Communications|May 31, 2019
Structure and immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus sequenceKwinten Sliepen, Byung Woo Han, Ilja Bontjer, et al.
The Lancet. Gastroenterology & Hepatology|August 3, 2019
Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trialCharlotte E L Klaver, Daniel D Wisselink, Cornelis J A Punt, et al.
Eclinicalmedicine|June 20, 2023
Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI): a cohort studyQuincy Hofsink, Sabine Haggenburg, Birgit I Lissenberg-Witte, et al.
JAMA Oncology|August 11, 2022
Antibody Response in Immunocompromised Patients With Hematologic Cancers Who Received a 3-Dose mRNA-1273 Vaccination Schedule for COVID-19Sabine Haggenburg, Quincy Hofsink, Birgit I Lissenberg-Witte, et al.
Gynecologic Oncology|July 1, 2026
Updated patient-reported outcomes and the effect of disease progression on health-related quality of life in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancerMark S Shahin, Domenica Lorusso, Floor J Backes, et al.
Nature Immunology|February 3, 2026
Identification of a potent V3 glycan site broadly neutralizing antibody targeting an N332<sub>gp120</sub> glycan-independent epitopeLutz Gieselmann, Andrew T DeLaitsch, Malena Rohde, et al.
Pageof 116